Modern Dose-Finding Designs for Cancer Phase I Trials: Drug Combinations and Molecularly Targeted Agents

1. Front Matter

   Pages i-xiii

   PDF

2. Dose Finding in Phase I Cancer Trials

   • Akihiro Hirakawa, Hiroyuki Sato, Takashi Daimon, Shigeyuki Matsui

   Pages 1-7

3. Dose Finding for a Combination of Two Agents

   • Akihiro Hirakawa, Hiroyuki Sato, Takashi Daimon, Shigeyuki Matsui

   Pages 9-40

4. Dose Finding for Joint Assessment of Both Efficacy and Toxicity

   • Akihiro Hirakawa, Hiroyuki Sato, Takashi Daimon, Shigeyuki Matsui

   Pages 41-58

5. Dose Finding for Molecularly Targeted Agents (MTAs)

   • Akihiro Hirakawa, Hiroyuki Sato, Takashi Daimon, Shigeyuki Matsui

   Pages 59-80

6. Advanced Topics on Dose-Finding Designs

   • Akihiro Hirakawa, Hiroyuki Sato, Takashi Daimon, Shigeyuki Matsui

   Pages 81-89

This book deals with advanced methods for adaptive phase I dose-finding clinical trials for combination of two agents and molecularly targeted agents (MTAs) in oncology. It provides not only methodological aspects of the dose-finding methods, but also software implementations and practical considerations in applying these complex methods to real cancer clinical trials. Thus, the book aims to furnish researchers in biostatistics and statistical science with a good summary of recent developments of adaptive dose-finding methods as well as providing practitioners in biostatistics and clinical investigators with advanced materials for designing, conducting, monitoring, and analyzing adaptive dose-finding trials. The topics in the book are mainly related to cancer clinical trials, but many of those topics are potentially applicable or can be extended to trials for other diseases. The focus is mainly on model-based dose-finding methods for two kinds of phase I trials. One is clinical trials with combinations of two agents. Development of dose-finding methods for two-agent combination trials requires reasonable models that can adequately capture joint toxicity probabilities for two agents, taking into consideration possible interactions of the two agents on toxicity probability such as synergistic or antagonistic effects. Another is clinical trials for evaluating both efficacy and toxicity outcomes in single- and two-agent combination trials. These methods are often applied to the phase I trials including MTAs because the toxicity and efficacy for a MTA does not monotonically increase with dose, but the efficacy often increases initially with the dose and then plateaus. Successful software implementations for several dose-finding methods are introduced in the book, and their operating characteristics in practice are discussed. Recent advance of the adaptive dose-finding methods in drug developments are also provided.

• Adaptive Design
• Cancer
• Dose Finding
• Phase I
• Phase I/II

• Department of Biostatistics and Bioinformatics, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan

  Akihiro Hirakawa

• Pharmaceuticals and Medical Devices Agency, Tokyo, Japan

  Hiroyuki Sato

• Division of Biostatistics, Hyogo College of Medicine Division of Biostatistics, Hyogo, Japan

  Takashi Daimon

• Depart Biostatis, Graduate Scl Med, Nagoya University Depart Biostatis, Graduate Scl Med, Nagoya, Japan

  Shigeyuki Matsui

- Akihiro Hirakawa, Department of Biostatistics and Bioinformatics, Graduate School of Medicine, The University of Tokyo
- Takashi Daimon, Division of Biostatistics, Hyogo College of Medicine
- Hiroyuki Satom, Biostatistics Group, Center for Product Evaluation, Pharmaceuticals and Medical Devices Agency
- Shigeyuki Matsui, Department of Biostatistics, Nagoya University Graduate School of Medicine

Policies and ethics